Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
2024-11-14 4:31 pm Sale | 13G | Kymera Therapeutics Inc. KYMR | Atlas Venture Fund X L.P. | 4,173,216 6.400% | -794,898 (-16.00%) | View |
2024-10-28 6:08 pm Purchase | 13D | Tectonic Therapeutic Inc. TECX | Atlas Venture Fund X L.P. | 67,567 0.500% | 67,567 (New Position) | View |
2024-04-01 9:52 pm Purchase | 13D | Q32 BIO INC QTTB | Atlas Venture Fund X L.P. | 864,261 7.200% | 864,261 (New Position) | View |
2024-02-09 4:05 pm Unchanged | 13G | GENERATION BIO CO GBIO | Atlas Venture Fund X L.P. | 7,111,939 10.800% | 0 (Unchanged) | View |
2024-02-09 4:03 pm Sale | 13G | Kymera Therapeutics Inc. KYMR | Atlas Venture Fund X L.P. | 4,968,114 8.400% | -98,811 (-1.95%) | View |
2024-01-25 4:38 pm Sale | 13D | Disc Medicine Inc. IRON | Atlas Venture Fund X L.P. | 1,402,186 5.800% | -191,599 (-12.02%) | View |
2023-09-21 4:44 pm Sale | 13D | Disc Medicine Inc. IRON | Atlas Venture Fund X L.P. | 1,593,785 7.000% | -643,518 (-28.76%) | View |
2023-09-15 4:56 pm Purchase | 13D | DIANTHUS THERAPEUTICS INC DNTH | Atlas Venture Fund X L.P. | 186,089 1.300% | 186,089 (New Position) | View |
2023-02-14 4:28 pm Sale | 13G | Kymera Therapeutics Inc. KYMR | Atlas Venture Fund X L.P. | 5,066,925 9.200% | -696,087 (-12.08%) | View |
2023-02-14 4:14 pm Purchase | 13D | Disc Medicine Inc. IRON | Atlas Venture Fund X L.P. | 2,237,303 12.900% | 2,237,303 (New Position) | View |
2022-12-06 5:00 pm Sale | 13D | Replimune Group Inc. REPL | Atlas Venture Fund X L.P. | 1,498,635 3.000% | -665,402 (-30.75%) | View |
2022-09-14 5:06 pm Sale | 13D | Replimune Group Inc. REPL | Atlas Venture Fund X L.P. | 2,164,037 4.400% | -360,829 (-14.29%) | View |
2022-05-05 4:01 pm Sale | 13D | DIANTHUS THERAPEUTICS INC DNTH | Atlas Venture Fund X L.P. | 2,977,448 5.100% | -379,892 (-11.32%) | View |
2022-02-11 5:12 pm Purchase | 13D | IKENA ONCOLOGY INC IKNA | Atlas Venture Fund X L.P. | 2,901,609 8.100% | 2,901,609 (New Position) | View |
2022-02-11 5:09 pm Sale | 13G | Kymera Therapeutics Inc. KYMR | Atlas Venture Fund X L.P. | 5,763,012 11.200% | -2,185,970 (-27.50%) | View |
2022-02-11 5:06 pm Sale | 13G | GENERATION BIO CO GBIO | Atlas Venture Fund X L.P. | 7,111,939 12.500% | -3,000,000 (-29.67%) | View |
2021-02-17 08:26 am Sale | 13D | DIANTHUS THERAPEUTICS INC DNTH | Atlas Venture Fund X L.P. | 3,357,340 7.000% | -759,785 (-18.45%) | View |
2021-02-16 5:29 pm Unchanged | 13D | SPERO THERAPEUTICS INC SPRO | Atlas Venture Fund X L.P. | 1,031,160 3.800% | 0 (Unchanged) | View |
2021-02-16 5:28 pm Purchase | 13G | GENERATION BIO CO GBIO | Atlas Venture Fund X L.P. | 10,111,939 21.700% | 10,111,939 (New Position) | View |
2021-02-16 5:27 pm Purchase | 13G | Kymera Therapeutics Inc. KYMR | Atlas Venture Fund X L.P. | 7,948,982 17.900% | 7,948,982 (New Position) | View |